comparemela.com

Latest Breaking News On - General counsel alicia - Page 1 : comparemela.com

Mitsubishi UFJ Asset Management UK Ltd Buys 7,000 Shares of NeoGenomics, Inc (NASDAQ:NEO)

Mitsubishi UFJ Asset Management UK Ltd Buys 7,000 Shares of NeoGenomics, Inc (NASDAQ:NEO)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Lisanti Capital Growth LLC Makes New $3 45 Million Investment in NeoGenomics, Inc (NASDAQ:NEO)

Lisanti Capital Growth LLC acquired a new position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) in the fourth quarter, Holdings Channel reports. The firm acquired 212,935 shares of the medical research company’s stock, valued at approximately $3,445,000. A number of other hedge funds and other institutional investors have also recently added to or reduced their […]

212,935 Shares in NeoGenomics, Inc (NASDAQ:NEO) Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 212,935 shares of the medical research company’s stock, valued at approximately $3,445,000. Lisanti Capital Growth LLC owned approximately 0.17% […]

Handelsbanken Fonder AB Has $322,000 Stock Position in NeoGenomics, Inc (NASDAQ:NEO)

Handelsbanken Fonder AB lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 7.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,900 shares of the medical research company’s stock after acquiring an additional 1,300 shares during the period. Handelsbanken Fonder AB’s holdings in NeoGenomics were worth $322,000 as of […]

NeoGenomics (NASDAQ:NEO) Stock Rating Reaffirmed by Benchmark

Benchmark reaffirmed their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $18.00 price objective on the medical research company’s stock. Other research analysts also recently issued reports about the company. William Blair restated an outperform rating […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.